Search results
Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight
Guru Focus· 17 hours agoAbbVie Inc (ABBV, Financial), a global biopharmaceutical powerhouse, filed its 10-Q report, revealing a comprehensive snapshot of its financial health and strategic positioning ...
...NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims - Comfort Systems USA (NYSE:FIX), ...
Benzinga· 1 day agoThe first-quarter 2024 earnings season is almost over as far as large drugmakers are concerned. Eli...
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
CNBC· 3 days agoSales of AbbVie's Humira are plummeting as the once-top-selling drug fights competition from cheaper...
Barclays lowers AbbVie shares target on Humira sales erosion concerns By Investing.com
Investing.com· 5 days agoThe revision was attributed to anticipated erosion of sales for Humira, a key drug in AbbVie's...
Better Dividend Stock: AbbVie or Johnson & Johnson?
Motley Fool via Yahoo Finance· 7 days agoWith 90 ongoing programs, AbbVie should be able to add brand-new products to its portfolio. Last year, the company earned approval for Epkinly, a new...
Investors Take AbbVie To The Woodshed. But Its Woes Are 'Unfounded.'Investors Take AbbVie To The...
Investor's Business Daily· 5 days agoOn Friday, AbbVie beat first-quarter expectations, largely on the back of its immunology franchise....
Coming to a CVS Near You: A Store Brand Monoclonal Antibody
The Wall Street Journal· 5 days agoBut this year the strategy changed. In...and replace it with biosimilars. There is a catch, though....
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Zacks via Yahoo Finance· 4 days agoThe Earnings Trends report indicates that as of Apr 24, 16.7... MRNA, Novo Nordisk NVO and Regeneron...
Trials to watch: Four ALS drugs to keep an eye on
Clinical Trials Arena via Yahoo Finance· 4 days agoHEALEY Platform trial investigates Calico and AbbVie drug The HEALEY ALS Platform Trial (NCT04297683) is a perpetual multi-centre, multi-regimen clinical...
CVS Caremark’s Policy Shift On Humira Biosimilars May Not Be What The Doctor Ordered
Forbes· 3 days agoAs of March, the blockbuster autoimmune drug Humira (adalimumab) still held 96% of the market share...
